Tetrabuthylammonium

Tetrabuthylammonium

SCHEMBL512903

CCCC[N+](CCCC)(CCCC)CCCC.O=C(O)c1cccc(Cl)c1

nearest known ligand 0.54

Full drug profile on Sugi Atlas →

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.52
HPGD P15428 1/20 0.52
OXER1 Q8TDS5 1/20 0.47
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
MAPT P10636 1/20 0.46
NR4A2 P43354 1/20 0.46
ERCC5 P28715 1/20 0.45
FEN1 P39748 1/20 0.45
PLA2G4B P0C869 1/20 0.45
EPHX1 P07099 3/20 0.45
PARP1 P09874 1/20 0.45
KMT2A Q03164 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tetrabuthylammonium SCHEMBL8765761 0.93 ALDH1A1 (0.47) ALDH1A1HPGDOXER1NPC1RAB9A
Tributylmethylammonium SCHEMBL9790214 0.90 ALDH1A1 (0.51) ALDH1A1HPGDOXER1NPC1RAB9A
Tetrabuthylammonium SCHEMBL107182 0.89 PLA2G4B (0.50) PLA2G4BKMT2A
Tetrabuthylammonium SCHEMBL159387 0.87 ALDH1A1 (0.51) ALDH1A1HPGDMAPTERCC5FEN1
Butylamine SCHEMBL6887552 0.83 ALDH1A1 (0.54) ALDH1A1HPGDOXER1NPC1RAB9A
Isophthalic Acid SCHEMBL28741411 0.83 KMT2A (0.47) HPGDPLA2G4BKMT2A
Tetrabuthylammonium SCHEMBL23045181 0.82 TSHR (0.54) ALDH1A1MAPTPLA2G4BKMT2A
Tetrabuthylammonium SCHEMBL108879 0.82 TSHR (0.54) ALDH1A1MAPTPLA2G4BKMT2A
Tetrabuthylammonium SCHEMBL107183 0.82 PLA2G4B (0.45) PLA2G4BKMT2A
Tetrabuthylammonium SCHEMBL11373850 0.82 PLA2G4B (0.45) PLA2G4BKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 321 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1675252-B Macromer combination and preparation method thereof JOHNSON & JOHNSON VISION CARE 2010-05-12 CN claimed
EP-1534759-B1 MACROMER FORMING CATALYSTS JOHNSON & JOHNSON VISION CARE (US) 2009-09-09 EP claimed
US-20060004119-A1 Macromer forming catalysts JOHNSON & JOHNSON VISION CARE, INC. 2006-01-05 US claimed
CN-1675252-A Macromer forming catalysts JOHNSON & JOHNSON VISION CARE (US) 2005-09-28 CN claimed
EP-1534759-A1 MACROMER FORMING CATALYSTS Johnson & Johnson Vision Care, Inc. (US) 2005-06-01 EP claimed
US-20040002556-A1 Macromer forming catalysts JOHNSON & JOHNSON VISION CARE, INC. 2004-01-01 US claimed
WO-2004000888-A1 MACROMER FORMING CATALYSTS JOHNSON & JOHNSON VISION CARE, INC. (US) 2003-12-31 WO claimed
US-4588795-A ADDITION POLYMERIZATION OF LIVING POLYMERS E. I. DU PONT DE NEMOURS AND COMPANY (US) 1986-05-13 US claimed
US-12636247-B2 Cosmetic SHIN-ETSU CHEMICAL CO., LTD. (JP) 2026-05-26 US disclosed
EP-4154970-B1 USE OF A DIBLOCK COPOLYMER AS EMULSIFIER SHINETSU CHEMICAL CO (JP) 2026-04-08 EP disclosed
US-12286543-B2 Image forming method Konica Minolta, Inc. (JP) 2025-04-29 US disclosed
CN-119781244-A Photosensitive composition for color filter, image display device, and solid-state imaging element 爱天思株式会社 2025-04-08 CN disclosed
CN-114341215-B Curable composition 株式会社日本触媒 2024-12-27 CN disclosed
EP-3805282-B1 METHOD FOR PRODUCING VINYL-ETHER-GROUP-CONTAINING (METH)ACRYLIC ACID ESTER POLYMER, VINYL-ETHER-GROUP-CONTAINING (METH)ACRYLIC ACID ESTER POLYMER, AND POLYMER COMPOSITION NIPPON CATALYTIC CHEM IND (JP) 2024-09-11 EP disclosed
EP-0251553-A2 Stabilized acrylic resin E.I. DU PONT DE NEMOURS AND COMPANY (US) 1988-01-07 EP disclosed
EP-0249436-A1 Group transfer polymerization and initiators therefor E.I. DU PONT DE NEMOURS AND COMPANY (US) 1987-12-16 EP disclosed
EP-0248596-A2 Durable epoxy (meth) acrylic polymer with oxirane-containing terminal groups and preparation E.I. DU PONT DE NEMOURS AND COMPANY (US) 1987-12-09 EP disclosed
WO-1987007265-A1 ACYLATION AND SULFONATION OF SILYLKETENE ACETALS E.I. DU PONT DE NEMOURS AND COMPANY (US) 1987-12-03 WO disclosed
EP-0244953-A1 Enhanced livingness of polymerization using silylated oxyanions E.I. DU PONT DE NEMOURS AND COMPANY (US) 1987-11-11 EP disclosed
EP-0243120-A2 Tough flexible polymer blends E.I. DU PONT DE NEMOURS AND COMPANY (US) 1987-10-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12636247-B2 Cosmetic MSR1, TLR3, LOXL1 ALDH1A1 459/4885HPGD 1753/4885OXER1 677/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.